About 1 in 4 patients with nonāsmall cell lung cancer have an unsatisfactory antibody response to the Omicron variant following COVID-19 vaccination, reports a new study.
MDedge News
1 in 4 Patients With NSCLC Respond Poorly to COVID-19 Vaccine
